Los fundamentos de la empresa son relativamente muy saludable. Su valoración está considerada valorada de forma justa,y su reconocimiento institucional es muy alto. Pese a que su rendimiento bursátil es débil, la empresa muestra unos fundamentos y datos técnicos sólidos. Las acciones se mantienen sin una tendencia clara entre los niveles de soporte y resistencia, así que son adecuadas para el swing trading en un mercado lateral.
Puntuación de PharmaCyte Biotech Inc
Información Relacionada
Ranking de la industria
220 / 407
Clasificación general
418 / 4616
Industria
Biotecnología e investigación médica
Resistencia y Soporte
Sin datos
Gráfico de radar
Precio actual
Anterior
Objetivo de los analistas
Basado en un total de
0
analistas
--
Calificación actual
--
Precio objetivo
--
Espacio en ascenso
Descargo de responsabilidad: Las calificaciones de los analistas y los precios objetivo son proporcionados por LSEG con fines informativos únicamente y no constituyen asesoramiento de inversión.
Aspectos destacados de PharmaCyte Biotech Inc
Puntos fuertesRiesgo
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Cambio hacia las ganancias
El rendimiento de la empresa ha pasado a ser rentable. Sus ingresos netos anuales más recientes han sido de USD.
Sobrevalorada
El PE más reciente de la empresa es 15.97, en un rango percentil alto de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 576.91K acciones, lo que supone una reducción del 45.69% con respecto al trimestre anterior.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.